Lifecore Biomedical, Inc. (LFCR) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Analysis Summary
Lifecore Biomedical, Inc. reported revenue of $129.5M in the most recent fiscal year, growing at a 5-year CAGR of 5.1%.
Trailing-twelve-month margins: gross margin 29.7%, operating margin -2.1%, net margin -30.4%.
At the current price of $4.16, LFCR has negative trailing earnings (P/E not meaningful) and an ROE of -376.95%. Market capitalisation stands at $156M.
Balance sheet quality for LFCR: current ratio of 3.5, net debt of $125.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $4.16 |
| Market Cap | $156M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 9.74 |
| EV / EBITDA | -73.17 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -376.95% |
| Return on Invested Capital | -1.25% |
| Return on Assets | -16.25% |
| Gross Margin | 29.68% |
| Operating Margin | -2.12% |
| Net Margin | -30.40% |
Financial Health
| Debt / Equity | 9.64 |
| Current Ratio | 3.87 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LFCR | Lifecore Biomedical, Inc. | $156M | 9.74 | -376.9% | |
| TAK | Takeda Pharmaceutical Company Limited | $59.3B | 50.64 | 1.20 | 2.4% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.9B | 58.46 | 5.53 | 9.2% |
| HLN | Haleon plc | $40.6B | 18.74 | 1.85 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.9B | 20.08 | 2.08 | 10.1% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price Performance
| 1 month | -5.02% |
| 3 months | -24.91% |
| Year-to-date | -49.14% |
| 1 year | -45.97% |
| 3 years | -49.02% |
| 5 years | -59.18% |
52-Week Range
| 52-week High | $8.98 |
| 52-week Low | $3.63 |
| Avg Volume (90d) | 177K |
Related companies: ACB · ACHV · BIOA · CGC · CVRX · IMMP · OMI
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of LFCR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks